GHP Specialty Care AB (GHP) (STO:GHP), a health care provider that operates specialist clinics in a select number of diagnostic areas, reported on Friday result after tax of SEK11.5m, or result per share of SEK0.13, for the second quarter of 2020.
This was a decline over result after tax of SEK12.7m, or result per share of SEK0.17, in Q2 2019.
Sales revenues for the quarter amounted to SEK317.0m, as compared with SEK335.7m in Q2 2019. Organic growth was a negative 8.2%.
According to GHP, revenues decreased in the quarter due to Covid-19 pandemic effects.
As a health care Group, GHP has had to manage the consequences of the COVID-19 pandemic at close quarters. In the Nordic Region it has lent personnel, material and equipment to the public hospitals, at the same time as it had to cancel the appointments of all risk-group patients.
Internationally, GHP adapted to taking care of almost only COVID-19 patients in the UAE, and in Kuwait the hospital is now temporarily a paediatric hospital.
(EUR1.00=SEK10.39)
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025